Navigation Links
Chemists' work with small peptide chains may revolutionize study of enzymes and diseases
Date:4/4/2014

Chemists in Syracuse University's College of Arts and Sciences have, for the first time, created enzyme-like activity using peptides that are only seven amino acids long.

Their breakthrough, which is the subject a recent article in Nature Chemistry magazine (Macmillan Publishers, 2014), may revolutionize the study of modern-day enzymes, whose chains of amino acids usually number in the hundreds, and of neurological diseases, such as Alzheimer's, which are usually characterized by small clumps of misshaped proteins called amyloids.

Their finding also supports the theory that amyloid fibrilsstrong, highly organized fibers, formed by proteins and peptidesmay have predated enzymes and triggered reactions that led to some of the earliest forms of life.

"Enzymes fold into unique three-dimensional structures, which underlie their remarkable catalytic properties and contribute to their large size," says Ivan V. Korendovych, assistant professor of chemistry at SU, who co-led the study with William DeGrado, professor of pharmaceutical chemistry at the University of California, San Francisco (UCSF). "Our goal was to prove that much shorter peptides can also achieve well-defined conformations through the formation of amyloid fibrils."

Korendovych and his team designed seven simple peptides, each containing seven amino acids. They then allowed the molecules of each peptide to self-assemble, or spontaneously clump together, to form amyloids. (Zinc, a metal with catalytic properties, was introduced to speed up the reaction.) What they found was that four of the seven peptides catalyzed the hydrolysis of molecules known as esters, compounds that react with water to produce water and acidsa feat not uncommon among certain enzymes.

"It was the first time that a peptide this small self-assembled to produce an enzyme-like catalyst," says Korendovych, an expert in bioinorganic chemistry, biophysics, and chemical biology. "Our finding suggests that amyloids, whose buildup leads to Alzheimer's in the brain, may also have served as the blueprint for larger, modern-day enzymes."

That's good news for researchers such as Korendovych, who thinks this finding may lead to the development of a new class of synthetic peptide-based catalysts. "The amyloid structures we've created may have a more complex biochemistry than we've realized," he says.

There are 20 naturally occurring amino acids, all of which serve as the building blocks of proteins and assist with metabolism.

An enzyme is a type of protein that is composed of at least 100 amino acids and speeds up reactions in a cell.

Korendovych says that, despite an astronomically large number of possible enzymes (each with a different amino acid sequence and three-dimensional shape), only a small number of them actually work.

"Each enzyme has to be an exact fit for its respective substrate," he says, referring to the molecule with which an enzyme reacts. "Even after millions of years, nature is still testing all the possible combinations of enzymes to determine which ones can catalyze metabolic reactions. Our results make an argument for the design of self-assembling nanostructured catalysts."


'/>"/>

Contact: Rob Enslin
rmenslin@syr.edu
315-443-3403
Syracuse University
Source:Eurekalert  

Related biology news :

1. Notre Dame chemists discover new class of antibiotics
2. Mentoring the next generation of black chemists (video)
3. CCNY chemists use sugar-based gelators to solidify vegetable oils
4. Biochemists find incomplete protein digestion is a useful thing for some bacteria
5. CCNY chemists devise new way to prepare molecules for drug testing
6. Biochemists uphold law of physics
7. University of Wisconsin chemists find new compounds to curb staph infection
8. UCI chemists devise inexpensive, accurate way to detect prostate cancer
9. Chemists devise inexpensive, benchtop method for marking and selecting cells
10. Chemists develop reversible method of tagging proteins
11. Chemists advance clear conductive thin films
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Chemists' work with small peptide chains may revolutionize study of enzymes and diseases
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: